Cardiff Oncology (CRDF) Receivables - Other (2022 - 2025)

Cardiff Oncology has reported Receivables - Other for 4 years, with the latest figure at $300000.0 in Q4 2025.

• Quarterly Receivables - Other fell 25.0% year-over-year to $300000.0 in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $300000.0 (down 25.0% YoY) and the FY2025 annual result came in at $300000.0, down 25.0% from the prior year.
• Receivables - Other declined to $300000.0 in Q4 2025 per CRDF's latest filing, from $400000.0 in the prior quarter.
• Over five years, Receivables - Other peaked at $600000.0 in Q4 2023 and troughed at $300000.0 in Q4 2025.
• A 4-year average of $450000.0 and a median of $450000.0 in 2022 frame the typical range for Receivables - Other.
• The sharpest annual moves came in 2023 and 2024: Receivables - Other gained 20.0% in 2023, then plunged 33.33% in 2024.
• Over 4 years, Receivables - Other stood at $500000.0 in 2022, then rose by 20.0% to $600000.0 in 2023, then plunged by 33.33% to $400000.0 in 2024, then retreated by 25.0% to $300000.0 in 2025.
• According to Business Quant data, Receivables - Other over the past three periods registered $300000.0, $400000.0, and $600000.0 for Q4 2025, Q4 2024, and Q4 2023 respectively.